Cargando…

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

Preclinical studies demonstrate that in vivo AQ4N enhances the anti-tumour effects of radiation and chemotherapeutic agents with a dose-modifying factor of approximately 2.0. With careful scheduling no, or very little, additional normal tissue toxicity should be observed. AQ4N is a bioreductive prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, L H, McKeown, S R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363465/
https://www.ncbi.nlm.nih.gov/pubmed/11104551
http://dx.doi.org/10.1054/bjoc.2000.1564